Electrical Stimulation for the Treatment of Pain and Muscle Rehabilitation
Medical coverage policy for the use of electrical stimulation devices (TENS, FES, NMES, and related modalities) for treatment of pain and muscle rehabilitation for UnitedHealthcare members.
Policy Summary
PayerUnitedHealthcare
PolicyElectrical Stimulation for the Treatment of Pain and Muscle Rehabilitation
Policy CodePolicy 2025T0126SS
Change TypeNo material change
Effective DateMay 1, 2025
Next Review Date
Key ActionObtain prior authorization or benefit verification and document indication, prior conservative therapies, and objective baseline functional measures when requesting coverage for electrical stimulation devices.
No material clinical or coverage changes in this revision.
SCI ambulationFES covered
Selected indicationsNMES covered
MultipleUnproven modalities
E0770HCPCS noted
13SCI studies
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.
FES is proven and medically necessary when ALL of the following are met:
FES SCI ambulation criteria: 1) Demonstration of intact lower motor units (L1 and below) (both muscle and peripheral nerves); 2) Muscle and joint stability for weight bearing at upper and lower extremities that can demonstrate balance and control to maintain an upright support posture independently; 3) Demonstration of brisk muscle contraction; 4) Demonstration of sensory perception sufficient for muscle contraction; 5) Demonstration of a high level of motivation, commitment, and cognitive ability for device use; 6) Ability to transfer independently; 7) Demonstration of independent standing tolerance for at least 3 minutes; 8) Demonstration of hand and finger function to manipulate controls; 9) Post-recovery from SCI and restorative surgery of at least 6 months; 10) Absence of hip and knee degenerative disease; 11) Absence of history of long bone fracture secondary to osteoporosis.
NMES is proven and medically necessary for treatment when ANY of the following indications apply:
NMES covered indications: 1) Disuse muscle atrophy when: a) nerve supply to the muscle is intact; and b) atrophy is non-neurological in origin (e.g., casting, splinting, contractures); OR 2) When used as part of a comprehensive lower limb rehabilitation program following total knee arthroplasty; OR 3) To improve upper extremity function in persons with partial paralysis following stroke when used as part of a comprehensive rehabilitation program.
Unproven / Not Medically Necessary modalities
Not medically necessary / unproven:
Unproven modalities: FES for indications other than SCI ambulation is unproven and not medically necessary; the following modalities are unproven and not medically necessary due to insufficient evidence of efficacy: Interferential therapy (IFT); Microcurrent electrical nerve stimulation (MENS); Percutaneous electrical nerve stimulation (PENS) / percutaneous neuromodulation therapy (PNT); Percutaneous electrical nerve field stimulation (PENFS); Percutaneous peripheral nerve stimulation (PNS); Peripheral subcutaneous field stimulation (PSFS) / peripheral nerve field stimulation (PNFS); Pulsed electrical stimulation (PES); Restorative neurostimulation; Scrambler therapy (ST); Translingual stimulation for gait rehabilitation (TS).
Footnotes reference other policies for occipital neuralgia/headache and DRG stimulation.
FES/NMES evidence for SCI
Evidence summaries and inferred clinical contexts (no explicit coverage decision language present in these chunks):
FES/NMES for spinal cord injury (SCI): Multiple studies (systematic reviews, cohort studies, RCTs) report physiologic and functional benefits of FES/NMES in persons with SCI, including increased V̇o2peak, muscle hypertrophy, improved muscle strength, reduced intramuscular fat, and improved quality of life; however, many studies are small and heterogeneous, leading to recommendations for larger RCTs.evidence graded as emerging/limited due to small sample sizes and heterogeneity
See chunks 32-36.
FES for cerebral palsy
FES for cerebral palsy (CP):
FES for unilateral spastic CP (peroneal nerve): A randomized cross-over trial found FES was not significantly superior to ankle-foot orthoses (AFO) for goal attainment or other standard measures; patient selection and testing period are important.evidence insufficient to show clear superiority
See chunk 37.
Coverage evidence framework
Evidence summary informing coverage decisions for FES in neurologic rehabilitation:
General evidence considerations: Coverage decisions should consider that multiple HTAs and systematic reviews report low-to-moderate quality and heterogeneous evidence for FES across indications; benefits are inconsistent and often small or device-dependentevidence quality
Refs: Hayes HTAs, ECRI, multiple meta-analyses
Indication-specific signals of benefit: Some RCTs and meta-analyses report improvements in gait speed, step length, ankle dorsiflexion, balance, functional mobility, or upper-extremity motor scores when FES is used versus no FES or versus supervised therapy in selected populationsstudy-reported outcomes
See Matsumoto et al., Zhu et al., Jaqueline da Cunha et al., Loh et al.
Limitations limiting broad coverage: Many studies are small, single-center, short duration, unblinded, use variable devices/parameters, and have inconsistent long-term durability of benefit
Coverage considerations by clinical population
Evidence-based coverage considerations derived from randomized trials and systematic reviews summarized in these sections
Neurologic rehabilitation (stroke, MS, SCI): FES/NMES shows some improvements in specific outcomes (e.g., ADLs when initiated early post-stroke in small studies; improved VO2 with FES-assisted cycling in severe MS; FES can improve walking speed in MS similar to AFOs) but evidence quality is often low and heterogeneous.evidence mixed/low quality
High-quality RCTs are lacking; benefits may depend on timing and device
Circulatory/CHF: Multiple RCTs and meta-analyses report FES can improve peak VO2, 6MWT, and QOL compared with control, and one RCT showed reduced HF hospitalizations after a 6-week program; conventional exercise may be superior for some outcomes.improvement in peak VO2/6MWT/QOL
Consider patient ability to perform conventional exercise
Critical care and ICU:
NMES for post-TKA rehabilitation
Covered when ALL of the following are met
Postoperative knee arthroplasty NMES benefit: Patients receiving NMES as an adjunct to standard rehabilitation initiated early after TKA showed attenuation of quadriceps strength loss and improved functional performance with effects most pronounced within the first month and persisting up to one year.initiation ~48 hours post-op; twice daily sessions
Evidence from a 66-participant RCT (Stevens-Lapsley et al., 2012).
NMES for post-THR edema prophylaxis
Considered when ALL of the following apply
Post-THR edema prophylaxis: NMES may be considered as an alternative to compression stockings for prevention of lower limb edema after THR based on a small feasibility RCT suggesting less edema at knee and thigh but with limited sample size and heterogeneity.continuous wear until discharge in study
Feasibility single-center RCT, N=40.
NMES for amputee rehabilitation
Covered when ALL of the following are met
Amputee rehabilitation with NMES: Home-based NMES adjunct to standard military amputee rehab improved early residual limb strength and pain compared to standard rehab alone, with benefits seen pre-prosthesis but no difference post-prosthesis at later timepoints.12-week program in study
Pilot RCT N=44 (Talbot et al., 2017).
NMES for cerebral palsy
Covered when ALL of the following are met
Pediatric CP NMES adjunct therapy: NMES applied as part of strengthening, gait training, or spasticity reduction programs in children with spastic cerebral palsy demonstrated potential benefits in strength, gait kinematics, and functional mobility, though protocols and dosages varied widely.programs ranged 4-48 weeks; many home-based
Scoping review and systematic reviews including multiple small RCTs (Greve 2022; Cobo-Vicente 2021; Pool 2016).
NMES for post-stroke dysphagia
Covered with criteria when ALL of the following are met
Post-stroke dysphagia: NMES combined with conventional swallowing therapy may improve swallowing function, quality of life, and reduce complications in post-stroke dysphagia versus swallowing therapy alone, with treatment courses typically 2-12 weeks; subgroup data suggest earlier treatment and shorter courses may show better response.course range 2-12 weeks; some analyses suggest <=4 weeks may be effective
Meta-analysis of 46 RCTs (3,346 participants) and systematic reviews (Wang 2023; Alamer 2020).
NMES and CCFES for post-stroke motor recovery
Covered when ALL of the following are met
Post-stroke upper limb motor recovery: NMES and variants (CCFES, cNMES) have demonstrated improvements in some measures of upper limb function and dexterity post-stroke; CCFES showed greater manual dexterity vs cyclic NMES in chronic moderate-severe impairment in one trial, while other trials show mixed superiority between CCFES and NMES.treatment durations in trials 3-12 weeks up to 12 weeks with home and lab sessions
Multiple RCTs and systematic reviews; benefits may be greater when applied in subacute stage or in severe paresis (Kristensen 2021).
Coverage considerations by condition/modality
Evidence-based coverage considerations gleaned from trials and reviews in this section:
Post-stroke upper extremity rehabilitation — evidence summary: CCFES showed greater improvement in manual dexterity (Box and Blocks Test) compared to cyclic NMES at six months in a single-center RCT of chronic stroke survivors; other measures (UEFMA, AMAT) did not show consistent between-group differences. Smaller RCTs reported CCFES superior to conventional NMES on some UE measures after short treatment courses.
Translatability to other centers and routine practice not established; evidence limited and mixed.
Respiratory/COPD and ICU-related NMES — evidence summary: NMES in hospitalized or mechanically ventilated COPD patients may improve quadriceps force and walking distance in some trials, but overall evidence quality is low and heterogeneous; Cochrane review found increased quadriceps force and walking distance with low/very low quality evidence.
NMES should not replace comprehensive pulmonary rehabilitation.
Perioperative and post-surgical NMES: A multicenter RCT (Takino et al.) found short-course postoperative NMES reduced percentage decline in knee extensor strength and walking speed at postoperative day seven compared to sham in older adults after cardiovascular surgery, with stronger effects in participants >75 years.
Evidence-based coverage considerations
Evidence summary guiding coverage interpretation
IFC/IFT for knee osteoarthritis: RCTs and meta-analyses report short- and some long-term pain improvements and functional gains with IFC/IFT versus control in knee OA, but heterogeneity and small trial sizes limit certainty; NICE recommends not offering IFT for OA due to inconsistent evidence.evidence mixed; consider conditional coverage with documented prior conservative therapy and standardized protocol
Some studies show benefit (pain, PPT, WOMAC); larger trials needed
IFC/IFT for postoperative TKA pain: Single RCT (Kadı et al. 2019) showed no significant differences in pain, ROM, or edema vs sham after TKA though reduced early analgesic use was noted but not sustained; evidence does not support routine use after TKA.no consistent benefit demonstrated
IFC/IFT or TENS for other musculoskeletal pain: Trials show mixed results: some RCTs report improvements when added to usual care, others find no advantage over sham or standard care; systematic reviews found IFC may relieve pain vs placebo but not when added to standard treatment and heterogeneity limits conclusions.
MENS / Microcurrent therapy evidence summary
Evidence from small RCTs and systematic reviews shows short-term modest pain reduction in some conditions; results are heterogeneous and limited by small sample sizes and variable methodologies.
Masticatory myofascial pain: Systematic review/meta-analysis (4 RCTs, pooled n=159; 3 in meta-analysis n=140) showed modest VAS reduction with MENS vs control but limitations include small trials and heterogeneity.
chunk 126
Knee and shoulder pain: Systematic review found MCT significantly improved shoulder and knee pain vs sham across several small RCTs/non-RCTs with no severe adverse events, but generalizability limited.
chunk 127
Acute knee pain RCT: Lawson et al. RCT (n=52) showed trends toward increased function, decreased pain, and decreased effusion with active MENS vs placebo; limitations include small size and short follow-up.
chunk 128
PENS/TEAS evidence summary (perioperative and musculoskeletal)
Multiple systematic reviews and RCTs demonstrate short-term reductions in postoperative pain, opioid consumption, PONV, and some functional improvements after TKA; PENS/TEAS show immediate to short-term analgesic effects, but heterogeneity and geographic concentration of studies limit generalizability and long-term effect evidence.
Perioperative TEAS benefits: Large systematic reviews/meta-analyses reported reduced pain scores within first 24-72 hours, reduced opioid consumption, and some improved functional scores after TKA; clinical importance varied and only some timepoints exceeded predefined VAS thresholds.VAS difference >1.0 cm considered clinically important in at least one review
chunks 133, 134, 139
TEAS reduces PONV and adverse reactions: Meta-analysis of 14 RCTs (n=1653) found TEAS lowered incidence of PONV, need for rescue antiemetic, dizziness and pruritis within 24-72 hours.
chunk 142
TEAS reduces postoperative POI: Gao et al. multicenter RCT (n=610) found TEAS lowered incidence of postoperative paralytic ileus by 8.7% and decreased risk by 32% after colorectal surgery.
Coverage observations and indication-specific conclusions
Coverage stance derived from evidence summaries and guidelines in this section:
PENS for painful diabetic neuropathy: Considered (recommended) by AAN/AANEM/AAPMR for treatment of painful diabetic neuropathy (Bril et al., 2011).
Guideline recommendation cited
PENS for chronic low back pain and other pain conditions: Evidence mixed: small RCTs and observational studies show variable short-term benefits; NICE concluded not recommended for low back pain due to low-quality evidence.
NICE found no sustained benefit after 4 months
PENFS for pediatric functional GI disorders/IBS: Several small RCTs, registry and observational studies report short-term improvement in abdominal pain and functional disability in pediatric populations but studies are limited by small size and short follow-up.
ECRI and Hayes analyses found limited/inconclusive evidence for IB-Stim in adolescents
PNS — Evidence synthesis
Evidence summary and implied coverage posture for PNS:
PNS evidence quality: Available studies include small RCTs, case series, and retrospective studies with generally low to very low quality; some show clinically meaningful pain and functional improvements but limitations prevent definitive conclusionsevidence strength
Hayes HTA concluded evidence insufficient for definitive efficacy/safety conclusions (2022, update 2024).
Positive signals: Select RCTs and prospective studies (Goree 2024, Gilmore 2023, Früh et al.) reported meaningful pain reduction and functional gains, and reductions in opioid use in some cohortsclinical signal
Study limitations include small sample sizes, nonrandomized designs, short follow-up or lack of controls
PES/PEMF — Evidence synthesis
Evidence summary and implied coverage posture for PES/PEMF:
PEMF evidence quality: Systematic reviews and RCTs show heterogeneous results; some meta-analyses report short-term pain or function benefits in osteoarthritis or postoperative settings but overall evidence is inconsistent and limited by heterogeneityevidence strength
AAOS gave a 'Limited' recommendation due to feasibility and limited access; further large RCTs recommended
Positive studies: D'Ambrosi (UKA) and several RCTs reported improved pain, function, and reduced NSAID use at multiple follow-ups; some studies showed no difference versus placebo depending on conditionclinical signal
Heterogeneous protocols and small sample sizes limit generalizability
Evidence summaries relevant to coverage
Summary of coverage-relevant evidence for modalities in this section
PEMF for knee osteoarthritis: Evidence from systematic reviews found only a few PEMF studies with pooled analysis showing statistically nonsignificant short-term pain benefit; evidence judged insufficient to assess effects on other outcomes; larger RCTs needed.
AAOS downgraded recommendation to 'Limited' due to feasibility/access concerns
Restorative neurostimulation for CLBP: Multiple studies including one randomized sham-controlled trial (n=240) and several long-term observational follow-ups report clinically meaningful improvements in pain, ODI, and QOL in selected refractory mechanical CLBP patients with multifidus dysfunction; limitations include high attrition and modest between-group effects at primary endpoint.
Device programming commonly twice daily stimulation; prior conservative management used in trials (>90 days medical management and PT)
Scrambler Therapy (ST/TEMPR): Systematic reviews and RCTs suggest ST may provide modest short-term pain reduction and reduce analgesic consumption for neuropathic pain (notably CIPN); evidence limited by small trials, heterogeneity, and short follow-up; guidelines do not recommend routine use outside trials.
Scrambler Therapy (ST) — evidence summary
Summary of evidence-based coverage stance for Scrambler Therapy and TLNS
Scrambler Therapy evidence and guideline context: Multiple systematic reviews and guideline statements find low to very low-quality evidence for Scrambler Therapy; ASCO does not recommend it outside clinical trials for CIPN and ESMO/EONS/EANO gives a D rating (not recommended).evidence quality low/very low
Further large, well-designed studies needed; safety profile appears favorable but effectiveness unproven
TLNS combined with physical therapy: RCTs and pilot studies show TLNS + targeted physical therapy may improve balance and gait in MS and mmTBI with some trials demonstrating sustained improvements; however, sample sizes and methodological limitations prevent definitive conclusions.limited sample size and variable follow-up
Additional larger trials and longer-term outcome data are required
Regulatory and device information
Device classification and regulatory notes
FDA device classifications and references: Multiple device types (IFT, PNS, PSFS/PNFS, MENS, PENS) have FDA product codes and some have 510(k) or de novo approvals; consult FDA product code listings for device-specific regulatory status.refer to FDA PMN/510k listings
Document device brand/model and product code when seeking coverage consideration
Device-specific coverage depends on meeting FDA-indicated criteria and prior therapy failure:
Restorative neurostimulation (ReActiv8) coverage conditions: Bilateral stimulation of the L2 medial branch as an aid in management of intractable chronic low back pain associated with multifidus muscle dysfunction in adults who have failed therapy including pain medications and physical therapy and are not candidates for spine surgery; diagnostic evidence via imaging or physiological testing required.N/A
Tied to PMA indication
This policy distinguishes modalities that are covered when specific, evidence‑based criteria are met from modalities that are considered unproven / not medically necessary due to insufficient or low‑quality evidence. For example, functional electrical stimulation (FES) is limited to the assistive/rehabilitative indication specified (lower‑limb ambulation after spinal cord injury) and only when the patient satisfies the listed clinical criteria; FES for other indications is explicitly stated as unproven and not medically necessary. Conversely, several other electrical stimulation approaches (including interferential therapy (IFT), microcurrent electrical nerve stimulation (MENS), percutaneous electrical nerve stimulation (PENS), percutaneous peripheral nerve stimulation (PNS), pulsed electrical stimulation (PES), restorative neurostimulation, scrambler therapy, and translingual stimulation) are listed as unproven or not medically necessary pending higher‑quality evidence. Coverage decisions therefore depend on the modality, the specific clinical indication, and whether the clinical documentation meets the defined criteria in this policy.
Where a modality is categorized as unproven or not medically necessary, the policy rationale references randomized trials and HTA findings that show inconsistent benefits, low quality evidence, or negative trial results; for example, randomized data have shown MENS was not superior to placebo for painful diabetic neuropathy and health technology assessments indicate limited or very‑low quality evidence for many percutaneous and implantable stimulation approaches. These evidence limitations underpin the policy’s exclusion of routine coverage for those modalities outside of clearly defined, evidence‑based indications or research settings.
Electrical stimulation modalities are heterogeneous in mechanism and intended effect; the policy therefore separates categories that produce sensory modulation from those intended to elicit muscle contraction or to provide targeted neuromodulation. For example, MENS delivers sub‑sensory, microampere‑range currents intended for pain relief and wound healing and is distinct from TENS, which operates in the milliampere range and produces perceptible sensations. By contrast, NMES and FES are designed to evoke muscle contractions to prevent disuse atrophy or enable functional movements, respectively. These distinctions are important because evidence and regulatory status differ by modality, and clinical indications and coverage criteria in this policy are modality‑specific rather than interchangeable.
Providers should document the exact modality and device type (for example, surface vs percutaneous vs implanted leads) and not assume therapeutic equivalence across device classes; the policy treats assistive versus rehabilitative FES uses separately and requires modality‑specific evidence to support coverage.
Health technology assessments and systematic reviews inform the policy’s exclusions. HTAs have generally found the body of evidence for many FES/NMES and percutaneous/implantable techniques to be small, heterogeneous, and of low to very low quality, recommending further standardized RCTs with longer follow‑up. These HTA findings contribute to placing several modalities in the unproven / not medically necessary category until higher‑quality evidence becomes available.
Specific trial findings that inform exclusion decisions include small randomized trials with negative or mixed results (for example, MENS not superior to placebo for painful diabetic neuropathy) and HTA conclusions that PENS/PNS evidence is very low or insufficient for many chronic low back pain indications. Where NICE or other guideline bodies explicitly recommend limiting use (e.g., NMES for dysphagia only with special arrangements, or recommending against offering IFT for certain musculoskeletal indications), the policy notes these observations as coverage‑limiting considerations.
Coding and Billing References
Referenced Category III / miscellaneous procedure codesCPT
0278T
Transcutaneous electrical modulation pain reprocessing (e.g., scrambler therapy), each treatment session (includes placement of electrodes).
0720T
Percutaneous electrical nerve field stimulation, cranial nerves, without implantation.
0783T
Transcutaneous auricular neurostimulation, set-up, calibration, and patient education on use of equipment.
Implantable neurostimulator CPT codesCPT
63650
Percutaneous implantation of neurostimulator electrode array, epidural.
63655
Laminectomy for implantation of neurostimulator electrodes, plate/paddle, epidural.
63663
Revision including replacement, when performed, of spinal neurostimulator electrode percutaneous array(s), including fluoroscopy, when performed.
63664
Revision including replacement, when performed, of spinal neurostimulator electrode plate/paddle(s) placed via laminotomy or laminectomy, including fluoroscopy, when performed.
63685
Insertion or replacement of spinal neurostimulator pulse generator or receiver, requiring pocket creation and connection between electrode array and pulse generator or receiver.
Insertion or replacement of percutaneous electrode array, peripheral nerve, with integrated neurostimulator, including imaging guidance, when performed; initial electrode array.
64597
Insertion or replacement of percutaneous electrode array, peripheral nerve, with integrated neurostimulator; each additional electrode array (List separately in addition to code for primary procedure).
64598
Revision or removal of neurostimulator electrode array, peripheral nerve, with integrated neurostimulator.
64999
Unlisted procedure, nervous system.
HCPCS and supply codes for external and implantable stimulatorsHCPCS | CPT | HCPCS
A4438
Adhesive clip applied to the skin to secure external electrical nerve stimulator controller, each.
A4543
Supplies for transcutaneous electrical nerve stimulator, for nerves in the auricular region, per month.
A4544
Electrode for external lower extremity nerve stimulator for restless legs syndrome.
A4556
Electrodes (e.g., apnea monitor), per pair.
A4557
Lead wires (e.g., apnea monitor), per pair.
A4593
Neuromodulation stimulator system, adjunct to rehabilitation therapy regime, controller.
A4594
Neuromodulation stimulator system, adjunct to rehabilitation therapy regime, mouthpiece, each.
A4595
Electrical stimulator supplies, 2 lead, per month, (e.g., TENS, NMES).
Independent standing toleranceDemonstration of independent standing tolerance for at least 3 minutes
Hand/finger functionDemonstration of hand and finger function to manipulate device controls
Transfer abilityAbility to transfer independently
Prior Authorization, Documentation, and Denial Risk
Prior Authorization
Verify benefits / Prior Authorization for listed codes
Verify member benefits and prior authorization requirements for the applicable CPT, HCPCS, and DME codes prior to scheduling or providing services. Coverage and prior authorization rules may vary by product and plan; contact UnitedHealthcare or the provider portal for plan-specific guidance.
Verify benefits / prior authorization for listed codes (CPT, HCPCS, DME) before services.
Contact payer/provider portal for plan-specific prior auth rules and medical necessity review.
Implantable restorative neurostimulation (for example, ReActiv8) typically requires prior authorization. When requesting authorization, provide device-specific indication documentation (see device indication below), prior conservative care, evidence of multifidus dysfunction (imaging or physiological testing), and documentation that the member is not a candidate for spine surgery.
Prior authorization recommended for implantable restorative neurostimulation devices (e.g., ReActiv8).
Required Conservative Care and Sequencing
Consider prior trial of conservative measures (AFO, supervised PT/exercise) when applicable
Consider prior trial of conservative measures when applicable:
Conservative alternatives before FES/NMES: Consider prior trial of conservative measures (e.g., ankle-foot orthosis for foot drop, supervised physical therapy/exercise programs) before initiating FES or NMES where evidence supports similar or incremental benefit of conservative care.
See comparative trials vs AFO and supervised exercise (chunks 45,52).
Documented trial or concurrent enrollment in standard therapy is expected when requesting NMES.
Documented trial or concurrent enrollment in standard therapy is expected when requesting NMES.
NMES concurrent/preceding standard therapy: Requests for NMES should document a trial of or concurrent enrollment in standard rehabilitation or swallowing therapy as applicable (e.g., conventional rehab after TKA, or swallowing therapy for dysphagia).
Most NMES trials evaluated NMES as adjunct to standard care (chunks 74,81,89).
Treatment Frequency, Duration, and Repeat Course Guidance
Implant therapy contextRestorative neurostimulation (implant) is a minimally invasive therapy targeting multifidus via leads placed beside the medial branch of the dorsal ramus
Stimulation schedule in trialsTherapy in ReActiv8 trial delivered twice daily stimulation sessions during the randomized period
Device exampleReActiv8 Implantable Neurostimulation System cited as example of restorative neurostimulation
inv-182: No explicit frequency limits provided in this excerpt.
No explicit frequency limitsNo explicit frequency limits or standardized session counts for many modalities are provided in this excerpt
Variation across studies
Imaging and Objective Assessment Requirements
Documentation Required
Document lead placement for restorative neurostimulation (operative report/imaging)
Implantation of restorative neurostimulation involves placement of leads adjacent to the medial branch of the dorsal ramus; include operative notes or imaging of lead placement when available to support device implantation claims.
Although the policy does not specify imaging requirements for placement, include intraoperative fluoroscopy or operative reports documenting lead location per device labeling.
Note
No explicit imaging requirements specified — follow device labeling and provide imaging when used
No general imaging requirements for device placement are specified in the cited excerpts; follow device labeling and include imaging or operative documentation when available.
If imaging was used for objective outcomes in trials, include those images or reports (e.g., MRI or VFSS) in the record.
Definitions and Device Terminology
Electrical stimulators apply controlled electrical waveforms to achieve therapeutic aims including muscle activation, pain modulation, wound healing, and functional assistance. Devices may deliver continuous, pulsed, alternating or direct current and differ by electrode type — surface/transcutaneous, percutaneous needle/probe, or implanted leads. Key device families in this policy include TENS (cutaneous sensory modulation), MENS (microcurrent, sub‑sensory), NMES (evoked muscle contraction for strength/rehabilitation), FES (functional task‑oriented stimulation), and percutaneous or implantable systems for peripheral or restorative neurostimulation.
The operational parameters (pulse width, frequency, amplitude) and lead/electrode configuration determine whether a device is intended to produce sensory effects (pain relief) versus motor effects (muscle contraction) and therefore which clinical indications and evidence apply. This background underpins the policy’s modality‑specific coverage criteria and documentation expectations.
inv-130: Electrical stimulators — general definition
General definitionElectrical stimulators deliver direct, alternating, pulsating and/or pulsed waveforms to exercise muscles, relieve pain, or provide test measurements; electrodes may be indwelling, implanted, transcutaneous, or surface
Device controlsDevices may include controls for pulse length, frequency, amplitude, and triggering modes
Uses
Modalities Not Covered or Considered Investigational
The policy lists modalities that are considered not covered / unproven because current evidence is insufficient to establish consistent clinical benefit. These include: Interferential therapy (IFT), Microcurrent electrical nerve stimulation (MENS), Percutaneous electrical nerve stimulation (PENS/PNT), Percutaneous electrical nerve field stimulation (PENFS), Percutaneous peripheral nerve stimulation (PNS), Peripheral subcutaneous field stimulation (PSFS/PNFS), Pulsed electrical stimulation (PES), Restorative neurostimulation (except where device indication and device‑specific criteria are met), Scrambler Therapy (ST), and Translingual stimulation for gait rehabilitation.
Where small randomized trials or HTAs specifically fail to show superiority or show only transient/uncertain benefits (for example, MENS not superior to placebo in a randomized trial of painful diabetic neuropathy), these findings support listing the modality as not medically necessary for the indicated usages.
Evidence limitations are an explicit reason for designating modalities as not covered. For instance, a randomized, sham‑controlled trial found MENS was not superior to placebo for painful diabetic neuropathy, and systematic reviews and HTAs have rated the quality of evidence for PENS and several percutaneous approaches as very low or insufficient to draw definitive conclusions. These outcomes — small sample sizes, short follow‑up, heterogeneity of devices and protocols, and inconsistent effect sizes — underpin the policy’s conclusion that such modalities remain investigational or not medically necessary outside of research or clearly defined device‑specific indications.
Accordingly, requests for coverage of these modalities should be supported by high‑quality, indication‑specific evidence and clear documentation of prior conservative therapies where applicable; absent that, coverage may be denied due to insufficient evidence of clinical benefit.
Background and Scope
Electrical stimulators encompass diverse device categories and clinical applications; broadly, they can: 1) produce sensory modulation to reduce pain perception (e.g., TENS, MENS), 2) produce muscle contractions to prevent disuse atrophy or enable function (e.g., NMES, FES), 3) deliver minimally invasive peripheral nerve stimulation via percutaneous leads (e.g., PNS), or 4) provide implantable restorative neuromuscular rehabilitation (e.g., devices targeting the multifidus).
The policy scope covers these modalities across pain and rehabilitation indications but sets distinct coverage rules: FES is covered only for the specified spinal cord injury ambulation indication when all clinical criteria are met; NMES is covered for defined indications (disuse atrophy, adjunct to post‑TKA rehab, and post‑stroke upper‑extremity rehabilitation) when criteria are satisfied; other modalities are considered investigational or not medically necessary without stronger evidence or device‑specific indications.
Key Clinical Thresholds and Metrics
11FES SCI criteria items
3NMES covered indications
11Modalities listed as unproven
Policy Revision History
2025-05-01effective_dateLatest
Policy effective date updated to May 1, 2025 with creation of shared policy version (2025T0126SS).
2025-05-01revision
Template update and creation of shared policy version to support application to Rocky Mountain Health Plans membership; removed language excluding Colorado and archived previous policy version 2025T0126RR.
Policy Summary
PayerUnitedHealthcare
PolicyElectrical Stimulation for the Treatment of Pain and Muscle Rehabilitation
Policy CodePolicy 2025T0126SS
Change TypeNo material change
Effective DateMay 1, 2025
Next Review Date
Key ActionObtain prior authorization or benefit verification and document indication, prior conservative therapies, and objective baseline functional measures when requesting coverage for electrical stimulation devices.
Large RCTs found no improvement in global muscle strength or long-term physical disability when adding FES/NMES to standard early rehabilitation in critically ill or mechanically ventilated patients.
no demonstrated benefit
Not routinely supported for improving long-term physical disability based on current RCTs
Orthopedic/postoperative use: Small RCTs and feasibility studies suggest NMES may reduce postoperative pain, swelling, and edema after total hip replacement and may help prevent DVT when combined with standard thromboprophylaxis, but evidence is limited and follow-up short.limited positive findings
Consider as adjunct in selected patients; evidence insufficient for broad coverage
Muscle strength/rehabilitation after ACL/amputation: Home-based NMES may prevent quadriceps weakness after ACL reconstruction and may accelerate residual limb strength recovery pre-prosthesis in amputees in small trials.prevent postoperative muscle weakness
Small sample sizes; supportive but preliminary evidence
NMES for prevention/treatment of hospital-acquired disability or ICU-AW: Systematic reviews/meta-analyses report small effects on muscle strength, walking performance, functional mobility and moderate effect on muscle size; heterogeneity and risk of bias limit certainty.
Clinical impact on discharge functional status inconsistent.
NMES for dysphagia (swallowing disorders): Systematic reviews found that NMES combined with swallowing therapy may improve swallowing outcomes but evidence is heterogeneous; NICE advises special arrangements for use in dysphagia and further high-quality trials are recommended.
Coverage likely limited to research settings or with strict oversight.
Interferential current (IFT/IFC) and TENS for musculoskeletal pain: Meta-analyses show IFT may reduce pain immediately post-treatment in NSCLBP and some trials show benefit in knee OA for short-term pain; overall heterogeneity and inconsistent long-term benefit limit broad recommendations.
Consider as adjunctive therapy with documented conservative care.
conditional/limited benefit; consider on individualized basis with documented functional improvement
results vary by condition and study quality
MENS/MCT for myofascial and other pain: Systematic reviews and small RCTs report modest short-term pain reductions with MENS in some conditions but studies are small and heterogeneous; evidence insufficient for broad coverage.insufficient high-quality evidence for broad coverage; may be considered experimental or investigational in many settings
authors recommend larger, standardized RCTs
Knee OA pilot RCT: Ranker et al. four-arm pilot RCT (n=52) reported reduced evening pain in MET groups vs sham/control; authors call for confirmation due to pilot nature.
chunk 130
Diabetic neuropathy trial: Gossrau et al. RCT (n=41) found MENS was not superior to placebo for painful diabetic neuropathy.
chunk 131
chunk 141
PENS immediate effects on PPT: Systematic review found immediate moderate effect of PENS/TENS on local pressure pain thresholds; short-term effects were not significant and long-term effects were not demonstrated.
chunk 135
PENS vs TENS: Review reported low-quality evidence favoring PENS over TENS for pain intensity but not clinically significant; authors do not recommend PENS as first-line based on current evidence.
chunk 138
TEAS pediatric perioperative analgesia: Small pediatric RCTs reported reduced postoperative pain and analgesic consumption with TEAS within 48 hours.
chunk 137
EA/electroacupuncture for CLBP: RCT found no significant difference in pain between real and sham electroacupuncture though post-hoc analyses showed reduced disability; limitations include short follow-up.
chunk 144
PNS for postoperative or chronic orthopedic pain: Recent multicenter RCT showed improved pain and function after TKA with 60-day PNS compared with placebo; overall evidence base remains limited and further large RCTs are needed.
Goree et al. (2024) reported 60% vs 24% ≥50% pain relief during weeks 5-8; limitations include small population and group imbalances.
General evidence sufficiency: For many indications (PNS for some neuropathies, PENFS for many GI indications, PENS for multiple pain types) evidence is weak/limited — consider not medically necessary or investigational where no guideline support or robust RCTs exist
Multiple evidence reviews and guideline statements point to insufficient evidence for broad support.
Typical ST protocols: 30-50 minutes per session for ~10 working days
inv-70: Post-recovery / restorative surgery period (ancillary clinical threshold)
Post-recovery / restorative surgery intervalPost-recovery from SCI and restorative surgery of at least 6 months
Absence of degenerative diseaseAbsence of hip and knee degenerative disease
Osteoporotic fracture historyAbsence of history of long bone fracture secondary to osteoporosis
Include device model and manufacturer, FDA indication, and PMA reference when available.
Document >90 days of medical management and at least one course of physical therapy prior to implant.
Prior Authorization
Prior authorization recommended for PNS
Prior authorization is recommended for peripheral nerve stimulation (PNS) — especially implantable or percutaneous systems — due to limited and evolving evidence. Requests should document conservative therapy attempts, trial outcomes (if a temporary lead trial was used), and any device-specific supporting data.
Prior authorization recommended for percutaneous and implantable PNS.
Provide trial-phase results, complications (explants, infections), and duration/intensity of prior conservative therapy.
Denial Risk
Unproven modalities may be denied
Unproven or insufficient-evidence modalities listed in policy (for example: MENS, PENS/PNT, PENFS, PSFS/PNFS, PES, restorative neurostimulation for some indications, scrambler therapy, translingual stimulation) may be denied as not medically necessary in the absence of sufficient high-quality evidence or when study limitations preclude generalizable benefit.
Unproven modalities may be denied for lack of demonstrated clinical benefit.
Submit high-quality, device-specific evidence and documentation of individualized rationale if requesting coverage exceptions.
Note
No stated step therapy rules in these chunks
No formal step therapy rules are stated for these electrical stimulation modalities in the reviewed chunks; however, document attempts at conservative therapy as applicable and follow payer-specific utilization management rules.
No step therapy rules specified in these sections — still verify plan-level requirements.
Document conservative care and rationale when seeking prior authorization.
Denial Risk
Lack of demonstrated benefit for mobility after sub-acute brain injury
For FES used in sub-acute acquired brain injury (including stroke or traumatic brain injury), evidence does not consistently demonstrate improved mobility in early/sub-acute phases; documentation should reflect realistic expectations and prior conservative therapy.
Lack of demonstrated benefit for mobility after sub-acute brain injury may affect coverage decisions.
Document baseline mobility, therapy intensity, and prior rehabilitation efforts when requesting services.
Denial Risk
Small / single-center or feasibility trial evidence limits generalizability
Many positive publications are small single-center or feasibility trials with limited generalizability. When such evidence is the primary support for an intervention, prior authorization reviewers may request larger, multi-center, blinded RCT data or decline coverage due to uncertainty of benefit.
Small single-center or feasibility trials limit generalizability and increase denial risk.
Provide larger, multicenter trial data or registries when available to support coverage.
Note
Special arrangements recommended by NICE for select indications
Follow NICE special arrangement guidance where applicable. For modalities where NICE recommends use only in research or special arrangements (for example: transcutaneous NMES for dysphagia), include documentation of consent, audit plans, and clinical governance if requesting authorization.
NICE: special arrangements recommended for NMES for dysphagia — include audit/research governance when applicable.
NICE recommendations against IFT, PENS, or TENS for certain indications may inform coverage decisions.
Denial Risk
Denial risk for insufficient evidence
Insufficient, low-quality, heterogeneous, or short-term evidence may trigger denials for the following therapies: percutaneous PNS, PENS/PNT, PENFS, scrambler therapy, some restorative neurostimulation indications, and other low-evidence modalities. Authorization requests should proactively address evidence gaps.
Denial risk for insufficient evidence across multiple modalities.
Provide clear, objective outcome measures, trial data, and justification for off-label or emerging-device requests.
Denial Risk
Insufficient evidence may trigger denial
Insufficient evidence or limited quality studies for a given modality may trigger denials. When requesting authorization, include detailed clinical rationale, prior conservative therapy, device-specific evidence, and, if available, enrollment in clinical trials or registries.
Insufficient evidence may trigger denial — include comprehensive documentation to mitigate risk.
Consider asking for case-by-case review or coverage with evidence development if applicable.
Denial Risk
Evidence limitations may trigger coverage denial
Evidence limitations (small populations, single-center design, lack of blinding, short follow-up, high attrition) across restorative neurostimulation and other implantable device studies have led to coverage uncertainty. Provide long-term follow-up data, independent replication, and intent-to-treat analyses to strengthen authorization requests.
Evidence limitations may trigger coverage denial for restorative neurostimulation and similar implantable devices.
When available, include multicenter RCTs, independent assessments, and longer-term outcome data.
Documentation Required
Device-specific indication documentation
Device-specific indication and coding details must be documented in authorization requests. Include device model, manufacturer, FDA indication or PMA reference (if applicable), and the specific CPT/HCPCS/L-codes to be billed.
Document device model/manufacturer and FDA/cleared indication (e.g., ReActiv8 PMA QLK).
List the exact CPT/HCPCS/L-codes intended for the procedure and supplies.
Documentation Required
NMES documentation requirements
For NMES and related transcutaneous therapies, include clear clinical documentation: diagnosis, treatment phase (initial vs continuation), concurrent standard therapies, objective baseline measures, treatment protocol (frequency, intensity, duration), and planned outcome measures. If NMES is adjunctive, document engagement in concurrent rehabilitation programs.
NMES documentation requirements: diagnosis, phase of care, concurrent therapy, baseline objective measures, and detailed treatment protocol.
Document that NMES is part of a comprehensive rehabilitation program when applicable.
Documentation Required
Device and indication documentation; Clinical notes should document diagnosis
Always include device and indication documentation in clinical notes: specific diagnosis, prior treatments tried (medications, PT, braces, injections), objective outcome measures (pain scores, functional scales, NYHA/LVEF for CHF, LEFS, ODI, VAS), and planned evaluation schedule. For implantable systems, record trial phase results, adverse events, and explant history.
Clinical notes should document diagnosis, prior conservative treatments, objective baseline measures, and planned outcomes.
For implants: document trial results, complications, and explant or infection history.
Documentation Required
Document outcome measures and treatment protocol
Document outcome measures and the full treatment protocol when submitting prior authorization or claims: specify scales used (e.g., VAS, ODI, LEFS, Fugl-Meyer, 6MWT), treatment frequency and duration, and pre/post objective testing. Include any functional improvement thresholds used to justify continuation or permanent implantation.
Document outcome measures (type and baseline values) and the treatment protocol (frequency, intensity, duration).
Include objective improvement thresholds and follow-up timing to support medical necessity determinations.
Consider prior conservative care before IFT/IFC
Consider prior conservative care before IFT/IFC:
Conservative care before IFT/IFC: Require documentation of prior conservative therapies (exercise, education, standard physical therapy) before authorizing IFT/IFC because systematic reviews report limited or short-term benefit and no clear long-term advantage.
See Rampazo et al. and Hussein et al. (chunk 106,118).
Documented trial of conservative therapy
Documented trial of conservative therapy is expected before certain electrical modalities:
Conservative therapy prerequisite: Require documented trial of standard conservative therapy (exercise, education, physical therapy) prior to consideration of IFC/IFT, MENS, PENS, or similar modalities given guideline statements advising against routine use without supportive evidence.
NICE guidance and systematic reviews referenced (chunks 118,123).
Document prior conservative therapies and access to trained PENS practitioner
Document prior conservative therapies and access to trained PENS practitioner when applicable:
PENS documentation and practitioner access: When PENS is requested, document prior conservative therapies and that a trained practitioner is available to perform PENS given feasibility concerns and guideline notes regarding practitioner training.
AAOS and review findings note requirement for trained practitioner (chunk 148).
Document failure of prior conservative therapies before considering implantable PNS
Document failure of prior conservative therapies is required before considering implantable PNS:
Implantable PNS conservative therapy failure: Before consideration of implantable PNS, document failure or intolerance of multiple prior conservative therapies including medications, physical therapy, injections and other noninvasive modalities.
Studies frequently included patients refractory to multiple nonsurgical treatments prior to implantation (chunks 165,167).
Documentation of failed conservative therapy including PT and medications (> 90 days)
Documentation of failed conservative therapy including PT and medications is expected:
ReActiv8 conservative therapy prerequisite: For restorative neurostimulation (ReActiv8), documentation should show > 90 days of medical management and at least one attempt of physical therapy prior to implantation.> 90 days
Reflects clinical trial eligibility and device indication (chunks 191,190).
Documentation of failed conservative therapies is required per device indication
Documentation of failed conservative therapies is required per device indication:
Device-specific conservative therapy documentation: Device-specific indications (eg, ReActiv8) require documentation of prior failed conservative therapies and diagnostic evidence (imaging or physiological testing) prior to coverage consideration.
See PMA labeling and device indications (chunk 218).
Study protocols and device parameters vary widely across trials and indications
Implication for authorizationAbsence of explicit limits suggests treatment frequency should match documented trial protocol or device labeling when seeking coverage
inv-183: FES training — commonly studied 6-week programs
Common training durationFES training programs in CHF and other trials commonly used 6-week training programs
Program intensityExamples include supervised sessions repeated multiple times per week as part of study protocols
Evidence implicationObserved clinical effects derive from defined trial courses (e.g., 6 weeks) so authorization should reference trial duration
inv-184: NMES treatment course — typical trial durations 2-12 weeks (some pediatric programs up to 48 weeks)
Typical NMES trial durationsNMES study regimens varied; typical trial durations reported were 2–12 weeks (many perioperative and dysphagia trials) with some pediatric programs up to 48 weeks
Postoperative initiationPost-TKA trials initiated NMES early (≈48 hours post-op) with twice-daily sessions in some RCTs
ACL/THR examplesSix-week home-based NMES programs prevented quadriceps weakness after ACL reconstruction in small RCTs; THR feasibility studies used multiple daily sessions over several days
inv-185: MENS/PENS treatment regimens varied widely — no standardized frequency limit specified
Regimens heterogeneousMENS and PENS regimens vary widely across trials (examples: 10 sessions over 3 weeks; daily 3-hour use for 4 weeks), with no standardized frequency limits specified
Session counts rangeStudies include single-session protocols, short multi-week series, and varied periprocedural schedules depending on indication
Evidence implicationLack of standardized dosing limits means authorization should reference the specific study protocol or manufacturer guidance
inv-186: PNS — leads left in up to 8 weeks in trials
Temporary lead duration in trialsIn multicenter PNS studies, percutaneous leads were left in place for up to 8 weeks during the treatment episode
Daily usage in case seriesSome PNS case series instructed daily use (eg, 6–12 hours/day for 60 days) with follow-up extending to 12+ months
Implant vs percutaneous distinctionPercutaneous PNS study regimens (temporary leads ~60 days) differ from implanted PNS systems in duration and management
inv-187: Percutaneous PNS — single 60-day percutaneous lead treatment courses common in studies
Common percutaneous coursePercutaneous PNS study regimens commonly used a single 60-day percutaneous lead treatment course (leads removed after ~8 weeks)
Crossover designsRandomized crossover trials allowed placebo participants to cross over to active PNS with similar 60-day lead placement
Repeat implant guidanceRepeat or longer percutaneous implants and long-term replacement strategies were not addressed in this excerpt
inv-188: Restorative neurostimulation — imaging/placement note (implantation requires lead placement next to medial branch)
Lead placement noteRestorative neurostimulation implantation involves placement of self‑anchoring leads next to the medial branch of the dorsal ramus
Target muscleTherapy targets the multifidus muscle to rehabilitate neuromuscular control in chronic mechanical low back pain
Imaging/physiologic evidenceDevice indication requires evidence of multifidus dysfunction by imaging or physiological testing per PMA labeling
Documentation Required
Trials used MRI or VFSS for objective muscle/swallowing assessments — include if available
When objective measures of muscle volume or swallowing function were used in trials, they included MRI for muscle volume and VFSS for dysphagia assessment; provide these study‑quality assessments when used to support coverage.
Attach MRI reports or VFSS results if these were used to demonstrate baseline dysfunction or treatment response.
Documentation Required
Include musculoskeletal ultrasound results when cited for MENS knee studies
Some MENS trials for knee pain used musculoskeletal ultrasound to assess effusion changes; include ultrasound reports when imaging-based objective outcomes are cited in support of coverage.
If musculoskeletal ultrasound was performed as an outcome measure, include pre/post images or formal radiology reports.
Documentation Required
No specified imaging requirement for PNS placement — provide procedural imaging if available
The cited policy excerpts do not specify imaging requirements for PNS lead placement; provide procedural notes and any imaging used for lead guidance when available to support claims.
Include details of target nerve, guidance technique (e.g., ultrasound, fluoroscopy), and dwell time when applicable.
Documentation Required
PNS placement — include imaging/procedure details when available
No specific imaging protocols for PNS placement are described in the policy excerpts; include procedural documentation and imaging used for placement per device labeling or study protocol.
Document lead trajectory, anatomical landmarks, and imaging guidance technique in operative or procedure notes.
Documentation Required
ReActiv8 requires imaging/physiologic evidence of multifidus dysfunction — include with request
Imaging or physiologic testing evidence of multifidus muscle dysfunction is required by the ReActiv8 implant indication; when requesting coverage, include this diagnostic evidence per the device PMA labeling.
Provide the referenced PMA product code (QLK) and the imaging/physiologic report demonstrating multifidus impairment.
Applications include muscle exercise, demonstrating muscular response to nerve stimulation, pain relief, and incontinence treatment
inv-131: MENS (Microcurrent) definition
MENS definitionMicrocurrent Electrical Nerve Stimulation (MENS) delivers microampere-range current intended for pain relief and wound healing; stimulus is sub-sensory and distinct from TENS
Regulatory categorizationMENS devices are often categorized under TENS product codes (eg, FDA product code GZJ) for regulatory convenience
Current magnitude exampleOne microamp (μA) = 1/1000 of a milliamp (mA); MENS uses microampere-range currents vs TENS which uses milliampere-range currents
MENS (alternate)Sub-sensorial microampere-range electrical stimulation intended for pain relief and wound healing; users cannot typically detect the stimulus
SynonymsAlso called micro electrical therapy (MET) or micro electrical neuro-stimulation
Clinical evidenceEvidence consists of small RCTs and case series with heterogeneous protocols; efficacy conclusions limited by small studies
PENS/PNT definitionPercutaneous Electrical Nerve Stimulation (PENS) is a minimally invasive technique using acupuncture-like needles connected to an external power source inserted percutaneously near painful areas
Regulatory statusPENS stimulators are FDA-regulated class II devices (Product Code NHI); several devices have FDA clearances
inv-135: Pulsed Electrical Stimulation (PES)
PES definitionPulsed Electrical Stimulation (PES) is hypothesized to facilitate bone and cartilage repair and alter inflammatory cell function via induced electrical fields
Biologic rationaleElectrostatic/electrodynamic fields may alter chondrocyte and osteoblast functions and influence cAMP or DNA synthesis in cartilage and bone cells
Evidence statusEvidence for PES/PEMF is heterogeneous and insufficient for many indications; larger RCTs are needed
inv-136: Restorative Neurostimulation definition
Restorative neurostimulation definitionImplant-based stimulation targeting the multifidus via leads placed next to the medial branch of the dorsal ramus to rehabilitate neuromuscular control in CLBP
Device example and approvalReActiv8 Implantable Neurostimulation System cited; granted PMA and indicated for bilateral L2 medial branch stimulation per labeling
Therapeutic intentIntended as rehabilitative therapy to restore multifidus function in patients with intractable mechanical CLBP who failed conservative therapies
inv-137: Scrambler Therapy (ST) definition
Scrambler Therapy definitionScrambler Therapy (ST) is a noninvasive transdermal electrotherapy applying variable nonlinear waveforms via dermatomal electrodes to present 'non-pain' information to painful areas
Typical protocolTypical ST protocols involve 30–50 minute sessions for approximately 10 consecutive working days in many studies
TENS definitionTranscutaneous Electrical Nerve Stimulation (TENS) delivers surface-electrode current to reduce pain perception by inhibiting afferent pain transmission and/or stimulating endorphin release
DistinctionTENS is primarily analgesic and distinct from neuromuscular stimulators that elicit muscle contractions
Device varietyClass II FDA-regulated devices with multiple product codes (eg, GZJ, NUH, NGX) and many commercial products
inv-139: CCFES definition
CCFES definitionContralaterally Controlled Functional Electrical Stimulation (CCFES) is an FES approach where movements of the contralateral limb control stimulation to the paretic limb to assist functional tasks
Clinical useStudied for post-stroke upper extremity rehabilitation and compared with cyclic NMES in RCTs
Therapy deliveryOften includes home and laboratory sessions over multi-week courses (eg, 3–12 weeks)
inv-140: Assistive vs Rehabilitative FES
Assistive vs rehabilitative FESAssistive FES provides functional assistance during tasks (eg, walking with foot drop) while rehabilitative FES aims to produce lasting motor recovery through therapeutic training
Device/indication differencesEvidence, devices, and trial protocols differ between assistive and rehabilitative uses—selection depends on treatment goal
Implication for coverageCoverage decisions should consider whether intended use is assistive (device replacement/orthotic aid) versus rehabilitative (therapeutic program)
inv-141: FES definition
FES termFunctional Electrical Stimulation (FES) applies electrical stimulation to produce functional movements (eg, cycling, foot drop correction) as part of rehabilitation
ApplicationsUsed in SCI ambulation programs, stroke rehabilitation, and assistive orthotic alternatives
Evidence variabilityStudy designs and devices vary; outcomes range from physiologic improvements to mixed functional benefits
inv-142: NMES definition
NMES termNeuromuscular Electrical Stimulation (NMES) is targeted stimulation of muscles to improve strength, circulation, and reduce edema via transcutaneous currents that elicit contractions
IndicationsUsed for disuse atrophy, post-operative rehabilitation (eg, TKA/THR), and as adjunct in neurologic rehab
Study durationsTrials commonly use multi-week courses (eg, 2–12 weeks) with variable session frequency and intensity
inv-143: CCFES detailed definition
CCFES detailed definitionCCFES uses contralateral limb movements to proportionally control stimulation to the paretic limb, enabling task-specific practice—studied versus cNMES for upper limb recovery post-stroke
Outcome measuresTrials measured Box and Blocks Test, UE Fugl-Meyer, AMAT and other functional outcomes at multiple follow-ups
Therapy courseOften delivered as daily or near-daily sessions over several weeks with adjunct functional practice
inv-144: Cyclic NMES (cNMES)
cNMES definitionCyclic NMES (cNMES) is a conventional NMES mode delivering periodic stimulation cycles for muscle activation in rehabilitation
Comparison contextCompared with CCFES in RCTs for post-stroke hand function; cNMES produced gains but sometimes less improvement in manual dexterity
Typical regimenDelivered in scheduled cycles often combined with home exercises and lab-based functional practice
inv-145: CCFES (alternate chunk)
CCFES alternate noteCCFES is an FES method controlled by contralateral limb movement to assist paretic limb tasks and has shown dexterity improvements in some trials vs cNMES
Clinical implicationMay be preferred in selected post-stroke patients with moderate impairment and within certain chronicity windows
Evidence cautionTranslatability to routine practice and across centers remains to be established
inv-146: IFT/IFC definition
IFT/IFC definitionInterferential Therapy (IFT/IFC) is a medium-frequency electrical therapy evaluated for chronic low back pain and knee OA to reduce pain sensitivity
Clinical findingsSome meta-analyses and network reviews identify IFC as promising for knee OA pain vs control but evidence heterogeneous and protocols inconsistent
Usage noteIFT/IFC is distinct from TENS and outcomes vary by condition, trial quality, and parameter settings
inv-147: MENS / Microcurrent Therapy (MCT) definition
MENS / MCT definitionMicrocurrent Therapy (MCT/MENS) applies very low-intensity microampere currents intended to reduce pain and promote healing; evidence from small RCTs is heterogeneous
Clinical contextsStudied in myofascial pain, knee/shoulder pain, and acute knee pain with short-term follow-up
Safety noteNo serious adverse events commonly reported in small trials but generalizability limited by small sizes and heterogeneity
inv-148: Interferential Therapy (IFC/IFT)
Interferential Therapy (IFC/IFT)A medium-frequency electrotherapy used for musculoskeletal pain (eg, knee OA) with some RCTs and network analyses suggesting short-term pain benefits but overall heterogeneous evidence
Trial parametersProtocols vary in session length, frequency, and electrode configuration—standardization lacking
Guideline tensionSome bodies (eg, NICE) recommend against routine offering in certain conditions due to inconsistent evidence
inv-149: MENS / Microcurrent therapy (duplicate)
MENS duplicate definitionMENS applies microampere-range currents for pain reduction and healing; small RCTs/meta-analyses show modest short-term benefits
Evidence limitationsConclusions limited by small trial numbers, heterogeneous protocols, and short follow-up
TerminologyAlso referred to as MET or micro electrical therapy
inv-150: TEAS definition
TEAS definitionTranscutaneous Electrical Acupoint Stimulation (TEAS) is noninvasive stimulation at acupoints often used perioperatively to reduce pain, opioid use, and PONV
Evidence volumeLarge systematic reviews include many RCTs (eg, 76 RCTs) indicating short-term reductions in postoperative pain and opioid consumption
Clinical importance thresholdSome pooled differences exceeded a predefined clinically important VAS change (eg, 1.0 cm) at certain timepoints
inv-151: PENS definition
PENS definitionPercutaneous Electrical Nerve Stimulation (PENS) uses percutaneously inserted probes/needles delivering electrical stimulation to peripheral nerves or trigger points for pain relief
Typical dosingStudies range from single-session protocols to multi-session courses (eg, up to 16 sessions), with heterogeneity in parameters
Comparative evidenceSystematic reviews show immediate moderate effects on pressure pain thresholds; clinical significance and long-term benefits remain uncertain
inv-152: PENS (alternate chunks)
PENFS definitionPercutaneous Electrical Nerve Field Stimulation (PENFS) often involves auricular or field stimulation via percutaneous probes to modulate gut-brain or neural circuits for functional abdominal pain and related disorders
Evidence baseEvidence includes small RCTs and registries, particularly in pediatric DGBI, with short-term improvements reported but limited control data
Regulatory noteIB-Stim (PENFS) has FDA De Novo clearance for adolescent functional abdominal pain (Product Code QHH)
inv-153: PENFS definition
PENFS (concise)Percutaneous electrical nerve field stimulation applies percutaneous probes (often auricular) to modulate neural circuits for GI and functional disorders; evidence limited
Usage contextUsed in pediatric DGBI and other functional disorders with registry and short-term trial data
Research needRobust RCTs with long-term follow-up recommended to confirm durability and comparative effectiveness
inv-154: PNS definition
PNS definitionPercutaneous Peripheral Nerve Stimulation (PNS) involves temporary percutaneous leads placed near peripheral nerves to deliver electrical stimulation for postoperative or chronic regional pain
Typical study regimenTrials often used a 60-day percutaneous lead course with leads removed after the treatment episode
Evidence statusEvidence includes small RCTs and case series with mixed quality; further large, multicenter RCTs needed
Percutaneous PNS definitionPlacement of percutaneous leads targeting peripheral nerves (eg, femoral, sciatic, saphenous, medial branch) to deliver stimulation, typically left in place for ~60 days in studies
Outcome signalsSome RCTs and case series report ≥50% pain relief and functional gains, but sample sizes and follow-up vary
Regulatory/product examplesDevices include StimRouter, SPRINT, and other commercial PNS systems with varying regulatory statuses
inv-156: PEMF/PES definition
PEMF/PES definitionPulsed Electromagnetic Field (PEMF) or Pulsed Electrical Stimulation (PES) are noninvasive pulsed electromagnetic/electrical field therapies applied externally with heterogeneous parameters across studies
Clinical targetsStudied for osteoarthritis, postoperative pain, chronic low back pain, and other musculoskeletal indications
Evidence statusSystematic reviews find heterogeneous and generally insufficient evidence; pooled PEMF results often nonsignificant and larger RCTs needed
inv-157: PEMF
PEMF concisePulsed Electromagnetic Field therapy applies noninvasive pulsed magnetic/electrical fields studied for knee OA with limited short-term pain benefit evidence
Study quantityFew PEMF trials exist for knee OA and pooled analyses show nonsignificant short-term pain effects
RecommendationFurther large RCTs needed to clarify clinical utility
ReActiv8 (Restorative neurostimulation) product noteReActiv8 Implantable Neurostimulation System cited with PMA approval for bilateral L2 medial branch stimulation in selected CLBP patients
Indication constraintsIndication requires failed conservative therapy, imaging/physiologic evidence of multifidus dysfunction, and that patient is not a candidate for spine surgery
Trial stimulation scheduleRandomized trial delivered twice-daily stimulation for 120 days during the blinded period
inv-159: Scrambler Therapy definition
Scrambler Therapy product noteCalmare/ST MC-5A device has FDA 510(k) clearance (product code GZJ) and subsequent model updates (eg, ST-5A)
Clinical evidenceSystematic reviews include small RCTs and observational studies; evidence limited by heterogeneity and short follow-up
Typical courseCommon study protocols involve ~10 sessions over 2 weeks with 30–50 minute sessions
Translingual Stimulation (PoNS) definitionTranslingual Stimulation (TLS/TLNS/PoNS) delivers neuromuscular stimulation to the tongue via a portable device as adjunct to supervised therapeutic exercise for gait/balance deficits
Regulatory pathwayPoNS device granted De Novo approval for adjunct short-term gait deficit treatment in MS (adults 22+)
Evidence notesRCTs show improvements when combined with PT in MS and mmTBI but sample sizes and generalizability are limited
inv-161: Scrambler Therapy (alternate chunk)
Scrambler Therapy alternateScrambler Therapy (ST/TEMPR) is a noninvasive electrotherapy intended to modulate pain signals, mainly studied for neuropathic pain including CIPN with mixed/low-quality evidence
Study follow-upMost trials have short follow-up (eg, ≤3 months), limiting assessment of long-term durability
Guideline cautionGuidelines (eg, ASCO/ESMO) do not recommend routine use for certain indications outside clinical trials
inv-162: MENS product code note
MENS product code noteMENS devices are categorized as TENS devices for regulatory listing (search Product Code GZJ)
Access linkFDA PMN/510(k) listings provide device-specific information (accessdata.fda.gov) for product code GZJ
ImplicationRegulatory categorization may not reflect mechanistic differences between MENS and TENS
inv-163: PENS / PENS product code note
PENS/PENFS product codesPENS stimulators are FDA-regulated class II devices (Product Code NHI); IB‑Stim (PENFS) has De Novo product code QHH for adolescent IBS indication
Device examplesDeepwave PENS system and IB‑Stim PENFS system referenced with PMN/510(k)/De Novo entries
Regulatory referenceRefer to FDA device databases for device-specific clearances and indications
Restorative Neurostimulation regulatory noteReActiv8 Implantable Neurostimulation System granted PMA (Product Code QLK) with labeled indication for bilateral L2 medial branch stimulation in selected CLBP patients
Indication requirementsPMA labeling requires imaging or physiologic evidence of multifidus dysfunction and prior failed conservative therapy; device intended for patients not candidates for spine surgery
Manufacturer exampleReActiv8 cited repeatedly in evidence and regulatory sections
Scrambler Therapy product codeCalmare/ST MC-5A device cleared by FDA (Product Code GZJ) with subsequent model updates
Regulatory vs evidenceFDA clearance/510(k) addresses device safety/market clearance but does not by itself establish clinical effectiveness across indications
Device lineageModel updates (eg, ST-5A) documented in FDA records
inv-166: TENS product code note
TENS product code noteTENS devices are FDA Class II with multiple product codes (eg, GZJ, NUH, NGX) and numerous commercial products—no exhaustive product list provided
Regulatory lookupRefer to FDA PMN/510(k) database by product code for device-specific details
Category implicationRegulatory classification does not homogenize clinical indications or protocols across TENS devices
inv-167: TLS / PoNS regulatory note
PoNS / TLS regulatory notePoNS translingual stimulator received De Novo approval for adjunct short-term gait deficit treatment in MS (adults 22+) under specified supervised exercise programs
Indication constraintsDe Novo approval limits use as adjunct to supervised therapeutic exercise by prescription
Evidence cautionEfficacy evidence is limited and centered on a small number of RCTs often from same research centers